{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:15:37Z","timestamp":1771931737134,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) and nodal T follicular helper cell lymphoma, angioimmunoblastic type (TFHL-AI) share significant histopathological and pathogenetic similarities. However, the mechanisms underlying these overlaps remain insufficiently explored in the literature. We report the case of a 74-year-old man who initially presented with progressive sore throat and was diagnosed with DLBCL, NOS based on a tonsillar biopsy. He achieved complete remission following six cycles of R-CHOP chemotherapy (rituximab, cyclophosphamide, vindesine, liposomal doxorubicin, and dexamethasone). However, the patient was lost to follow-up. About two years later, he re-presented with generalized pruritus and lymphadenopathy. A cervical lymph node biopsy confirmed TFHL-AI. He received four cycles of the histone deacetylase inhibitor (HDACi) chidamide combined with COEP chemotherapy (cyclophosphamide, vindesine, etoposide, and prednisone), resulting in a partial remission. However, the disease subsequently progressed, and the patient passed away six months later, with a total overall survival of 35months. Next-generation sequencing (NGS) of biopsy specimens from both lymphoma types revealed shared\n                    <jats:italic>TET2<\/jats:italic>\n                    mutations. These findings suggest that\n                    <jats:italic>TET2<\/jats:italic>\n                    mutations may drive clonal evolution and reprogram the tumor microenvironment, potentially facilitating divergent evolution from a common mutated precursor or the sequential development of distinct lymphoid neoplasms. This case highlights the diagnostic and therapeutic challenges of TFHL-AI following DLBCL, NOS. Although the prognosis is generally poor, treatment combining HDAC inhibitors such as chidamide with chemotherapy may offer therapeutic potential. Further studies are needed to clarify the molecular mechanisms underlying such lymphoid evolution and to guide optimal management.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1698958","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:38:55Z","timestamp":1770964735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Born with two faces: sequential DLBCL, NOS and TFHL-AI with TET2 mutation \u2013 a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Qing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shishuo","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenlu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00898","article-title":"Genomics of peripheral T-cell lymphoma and its implications for personalized medicine","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001371","article-title":"Epstein-barr virus-induced cutaneous diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma","volume":"41","author":"Poon","year":"2019","journal-title":"Am J Dermatopathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e04083","DOI":"10.1002\/ccr3.4083","article-title":"Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma Transformed into Angioimmunoblastic T-Cell Lymphoma after Treatment","volume":"9","author":"Wang","year":"2021","journal-title":"Clin Case Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-022-01764-1","article-title":"A comparison of the international consensus and 5th world health organization classifications of mature B-cell lymphomas","volume":"37","author":"Falini","year":"2023","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015451","article-title":"Clonal germinal center B cells function as a niche for T-cell lymphoma","volume":"140","author":"Fujisawa","year":"2022","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/path.4898","article-title":"Tet2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma","volume":"242","author":"Schwartz","year":"2017","journal-title":"J Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1038\/bcj.2016.122","article-title":"Identification of cell-type-specific mutations in nodal T-cell lymphomas","volume":"7","author":"Nguyen","year":"2017","journal-title":"Blood Cancer J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225699","article-title":"Targeting tet2 as a therapeutic approach for angioimmunoblastic T cell lymphoma","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285183","article-title":"Polytypic B cells, monotypic\/monoclonal B-cell proliferations, and neoplastic T cells diverge from tet2-\/dnmt3a-mutant clonal hematopoiesis in follicular helper T-cell lymphomas","volume":"110","author":"Lewis","year":"2025","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3778","article-title":"Overlap between ebv-positive diffuse large B-cell lymphoma, nos, in a young patient and angioimmunoblastic T-cell lymphoma: A diagnostic pitfall","volume":"9","author":"Kim","year":"2021","journal-title":"Clin Case Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2018-z","article-title":"Independent growth of diffuse large B cell lymphoma and angioimmunoblastic T cell lymphoma originating from composite lymphoma","volume":"93","author":"Tabata","year":"2014","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102392","article-title":"Novel T follicular helper-like T-cell lymphoma therapies: from preclinical evaluation to clinical reality","volume":"14","author":"Krug","year":"2022","journal-title":"Cancers. (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, nccn clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000773","article-title":"Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment","volume":"33","author":"Tari","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: A multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B18","article-title":"Development of angioimmunoblastic T-cell lymphoma after treatment of diffuse large B-cell lymphoma: A case report and review of literature","volume":"7","author":"Wang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B19","article-title":"Angioimmunoblastic T-cell lymphoma mimicking diffuse large B-cell lymphoma","volume":"102","author":"Ellis","year":"2018","journal-title":"Cutis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3760\/cma.j.issn.0253-2727.2020.11.017","article-title":"Pathological transformation of angioimmunoblastic T-cell lymphoma into diffuse large B-cell lymphoma: A case report","volume":"41","author":"Quan","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.940513","article-title":"Case report: immune microenvironment and mutation features in a patient with epstein-barr virus positive large B-cell lymphoma secondary to angioimmunoblastic T-cell lymphoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-7-7","article-title":"Secondary cutaneous epstein-barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: A case report and review of literature","volume":"7","author":"Yang","year":"2012","journal-title":"Diagn Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdcr.2022.04.029","article-title":"Epstein-barr virus-positive, cd30-positive, diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma","volume":"25","author":"Grossman","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B24","article-title":"Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Skugor","year":"2010","journal-title":"Coll Antropol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2018.2018.0023","article-title":"Ebv-related diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma","volume":"36","author":"Simsek","year":"2019","journal-title":"Turk J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/dc.21641","article-title":"Sequential development of diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma","volume":"40","author":"Huang","year":"2012","journal-title":"Diagn Cytopathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1698958\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:28:46Z","timestamp":1771928926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1698958\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1698958"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1698958","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1698958"}}